Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
InflaRx $30 million offering of ordinary shares and pre-funded warrants
The ordinary shares are listed on the Nasdaq Global Market
NeuroPace $74.75 million follow-on offering
The stock is listed on the Nasdaq Global Market
Oculis Holding $100 million follow-on equity offering
The shares are listed on the Nasdaq Global Market and the Nasdaq Iceland Main Market
BioVersys CHF 80 million IPO and concurrent private placement
We advised AMR Action Fund on its investment in BioVersys
Eli Lilly $6.5 billion notes offering
The investment-grade notes are due 2028, 2030, 2032, 2035, 2055 and 2065
McKesson $850 million acquisition of controlling interest in PRISM Vision
We are advising McKesson on the transaction
GH Research $150 million follow-on offering
We advised GH Research on the offering of shares
Maze Therapeutics $140 million IPO
The shares are listed on Nasdaq
Global pharmaceutical company in congressional inquiry
We are representing the client in an inquiry regarding certain online platforms
Ascentage Pharma $126.4 million IPO
The IPO is the first life sciences U.S. IPO of 2025 and the first life sciences company listed on the HKEX to complete a U.S…